These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8533125)

  • 21. Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia.
    Boquist S; Karpe F; Danell-Toverud K; Hamsten A
    Atherosclerosis; 2002 May; 162(1):163-70. PubMed ID: 11947910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apolipoprotein E enrichment of immuno-separated chylomicron and chylomicron remnants following saturated fatty acids.
    Jackson KG; Wolstencroft EJ; Bateman PA; Yaqoob P; Williams CM
    Nutr Metab Cardiovasc Dis; 2006 Sep; 16(6):405-17. PubMed ID: 16935699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Remnant-like lipoproteins stimulate whole blood platelet aggregation in vitro.
    Knöfler R; Nakano T; Nakajima K; Takada Y; Takada A
    Thromb Res; 1995 Apr; 78(2):161-71. PubMed ID: 7482433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A proposal linking atherogenesis to the interaction of endothelial lipoprotein lipase with triglyceride-rich lipoproteins.
    Zilversmit DB
    Circ Res; 1973 Dec; 33(6):633-8. PubMed ID: 4361710
    [No Abstract]   [Full Text] [Related]  

  • 25. Kinetics of triglyceride rich lipoproteins: chylomicrons and very low density lipoproteins.
    Hugh P; Barrett R
    Atherosclerosis; 1998 Dec; 141 Suppl 1():S35-40. PubMed ID: 9888640
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased platelet aggregation during alimentary hyperlipemia in normal and hypertriglyceridemic subjects.
    Fuhrman B; Brook JG; Aviram M
    Ann Nutr Metab; 1986; 30(4):250-60. PubMed ID: 3752924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paraoxonase 1 activity in chylomicrons and VLDL: the effect of type 2 diabetes and meals rich in saturated fat and oleic acid.
    Manning PJ; Jong SA; Ryalls AR; Sutherland WH
    Lipids; 2012 Mar; 47(3):259-67. PubMed ID: 22160450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chylomicron-like particles in severe hypertriglyceridemia.
    Aviram M; Sechter Y; Brook JG
    Lipids; 1985 Apr; 20(4):211-5. PubMed ID: 3999928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma very low density lipoprotein (VLDL) in cholesterol-fed rabbits: chylomicron remnants or liver lipoproteins?
    Thompson KH; Zilversmit DB
    J Nutr; 1983 Oct; 113(10):2002-10. PubMed ID: 6619979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibrinolytic and thrombotic factors in atherosclerosis and IHD: the influence of triglyceride rich lipoproteins (TGRLP).
    Bradley WA; Booyse FM; Gianturco SH
    Atherosclerosis; 1994 Aug; 108 Suppl():S31-9. PubMed ID: 7802727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postchallenge plasma lipoprotein retinoids: chylomicron remnants in endogenous hypertriglyceridemia.
    Wilson DE; Chan IF; Buchi KN; Horton SC
    Metabolism; 1985 Jun; 34(6):551-8. PubMed ID: 3999977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia.
    Guerin M; Egger P; Le Goff W; Soudant C; Dupuis R; Chapman MJ
    J Clin Endocrinol Metab; 2002 Nov; 87(11):4991-5000. PubMed ID: 12414863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolism of triglyceride-rich lipoproteins during alimentary lipemia.
    Karpe F; Steiner G; Olivecrona T; Carlson LA; Hamsten A
    J Clin Invest; 1993 Mar; 91(3):748-58. PubMed ID: 8450056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postprandial remnant-like lipoproteins in hypertriglyceridemia.
    Ooi TC; Cousins M; Ooi DS; Steiner G; Uffelman KD; Nakajima K; Simo IE
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3134-42. PubMed ID: 11443178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia.
    Guerin M; Le Goff W; Duchene E; Julia Z; Nguyen T; Thuren T; Shear CL; Chapman MJ
    Arterioscler Thromb Vasc Biol; 2008 Jan; 28(1):148-54. PubMed ID: 17951324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between triglyceride-rich lipoprotein (chylomicrons and VLDL) and HDL2 and HDL3 in the post-prandial phase in humans.
    Baggio G; Fellin R; Baiocchi MR; Martini S; Baldo G; Manzato E; Crepaldi G
    Atherosclerosis; 1980 Oct; 37(2):271-6. PubMed ID: 7426099
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review.
    Oscarsson J; Hurt-Camejo E
    Lipids Health Dis; 2017 Aug; 16(1):149. PubMed ID: 28797250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postprandial remnant lipoproteins as targets for the prevention of atherosclerosis.
    Nakajima K; Tanaka A
    Curr Opin Endocrinol Diabetes Obes; 2018 Apr; 25(2):108-117. PubMed ID: 29493553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human intestinal lipoproteins. Studies in chyluric subjects.
    Green PH; Glickman RM; Saudek CD; Blum CB; Tall AR
    J Clin Invest; 1979 Jul; 64(1):233-42. PubMed ID: 221544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.